A phase I, randomized, double-blind, parallel, single-dose pharmacokinetic study to evaluate the biosimilarity of KM118 (proposed pertuzumab biosimilar) with reference pertuzumab (... by Yan Li, Yu Wang, Caixia Yang, Na Zhao, Xinghe Wang

Subjects: Get full text

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER by O. I. Kit, L. Yu. Vladimirova, E. A. Kalabanova, A. E. Storozhakova, S. N. Kabanov, T. A. Snezhko, I. S. Mitashok, Ya. V. Svetitskaya, N. Yu. Samaneva, I. S. Kornilova, Yu. V. Przhedetskiy, V. V. Pozdnyakova, N. A. Abramova, I. L. Popova, N. M. Tikhanovskaya, A. A. Lyanova, K. A. Novoselova, L. A. Ryadinskaya

Subjects: Get full text

Pharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery system by Chris Wynne, Bei Wang, Rong Deng, Junyi Li, Daniel Eiger, Fabiola Bene Tchaleu, Sarah Heeson, Eleonora Restuccia

Subjects: Get full text

Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy? by Wiebren Tjalma, Laure-Anne Teuwen, Sevilay Altintas, Konstantinos Papadimitriou

Subjects: Get full text

Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study by Junxiao Wang, Yushuai Yu, Qisheng Lin, Xin Wang

Subjects: Get full text

HER-2-positive metastatic breast cancer: new possibilities for therapy by E. V. Artamonova, L. V. Manzyuk

Subjects: Get full text

In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with 225Ac by Kateřina Ondrák Fialová, Lukáš Ondrák, Martin Vlk, Ján Kozempel, Kateřina Nováková, Zbyněk Nový, Katarína Hajduová, Marián Hajdúch, Miloš Petřík, Marek Pruszynski, Frank Bruchertseifer, Alfred Morgenstern

Subjects: Get full text

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo by Zheng Wang, Yu Liu, Yunxia Xu, Lin Lu, Zhen Zhu, Baojie Lv, Xin Fang, Yao Tang, Jinhua Wang, Yu Cheng, Ying Hu, Junwen Lou, Peican Wu, Chendan Liu, Yanjun Liu, Xin Zeng, Qing Xu

Subjects: Get full text

Development of Focal Nodular Hyperplasia Post Dual Anti-HER2 Blockade with Pertuzumab and Trastuzumab in a Patient with Breast Cancer: A Case Report and Literature Review by Udip Maheshwari, Disha Morzaria, Vashishth Maniar, Ritu Dave, Nikhat Shaikh, Bhavin Jankharia, Karthik Ganesan

Subjects: Get full text

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case) by A.   F. Nasretdinov, A.   V. Pushkarev, O.  N.  Lipatov, N.   I. Sultanbaeva, Sh.   I. Musin, K.   V. Menshikov, A.   A. Izmailov, V.   A. Pushkarev, M.   G. Galeev, R.   R. Muginov, R.   B. Valiakhmedov, D.   D. Sakaeva, A.   V. Sultanbaev

Subjects: Get full text

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade by V. F. Semiglazov, N. B. Bekkeldieva, P. V. Krivorotko, A. V. Komyakhov, R. M. Paltuev, A. I. Tseluyko, L. P. Gigolaeva, T. T. Tabagua, E. K. Zhiltsova, V. S. Apollonova, G. A. Dashyan, A. G. Kudaybergenova, V. G. Ivanov, A. A. Bozhok, D. G. Ulrikh, A. O. Gorina, T. Yu. Semiglazova

Subjects: Get full text

Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting by Jian Zhang, Jian Zhang, Jian Zhang, Yuxin Mu, Yuxin Mu, Yuxin Mu, Hui Zhang, Chao Deng, Jiao Yang, Lu Gan, Qingmo Yang, Xuefeng Xu, Wanping Liang, Xiaowei Qi, Liang Xu

Subjects: Get full text

Patient's journey with HER2 positive breast cancer: difficulties in the access to treatment and new technologies in the Brazilian public health system by Cibele Rosalin Oliveira, Maria Aparecida Nicoletti

Subjects: Get full text